ASKA Pharmaceutical Holdings CO., Ltd.

4886.TJapan

18 filed reports · 262 financial concepts

Latest figures

Group totals as stated in the company’s own filed reports, each with a link to its report. The change is against the same period a year earlier.

Latest fiscal year

Revenue

¥71.1B

FY2026 · to Mar 31, 2026

up +10.9% vs ¥64.1B

Half-year report

Net income

¥5.63B

FY2026 · to Mar 31, 2026

up +10.3% vs ¥5.1B

Annual report

Operating income

¥5.83B

FY2026 · to Mar 31, 2026

up +9.4% vs ¥5.33B

Annual report

Latest half year

Revenue

¥35.6B

H1 FY2027 · to Sep 30, 2026

up +1.1% vs ¥35.3B

Half-year report

Net income

¥2.1B

H1 FY2027 · to Sep 30, 2026

down −11.0% vs ¥2.36B

Half-year report

Operating income

¥2.74B

H1 FY2027 · to Sep 30, 2026

up +3.5% vs ¥2.65B

Half-year report

Filed reports

18 reports · Jun 2021 to Sep 2026

Each report counts once it has at least one extracted financial fact.

Report typeReportsFactsPeriods
Annual · annual securities reportEDINET51,471Mar 2022 to Mar 2026
Half Year · half-year securities reportEDINET3701Sep 2024 to Sep 2026
Q3 · quarterly securities reportEDINET3350Dec 2021 to Dec 2023
Half Year · quarterly securities reportEDINET2384Sep 2022 to Sep 2023
Q1 · quarterly securities reportEDINET2338Jun 2022 to Jun 2023
Half Year · amended quarterly securities reportEDINET146Sep 2021
Q1 · amended quarterly securities reportEDINET147Jun 2021
Q3 · amended quarterly securities reportEDINET142Dec 2021

Documents

PeriodTypePeriod endPublishedFactsSource
FY2027 H1half-year securities report2026-09-302026-11-09316Open
FY2026annual securities report2026-03-312026-06-19622Open
FY2026 H1half-year securities report2025-09-302025-11-07194Open
FY2025annual securities report2025-03-312025-06-20281Open
FY2025 H1half-year securities report2024-09-302024-11-08191Open
FY2024annual securities report2024-03-312024-06-25280Open
FY2024 Q3quarterly securities report2023-12-312024-02-09201Open
FY2024 H1quarterly securities report2023-09-302023-11-10192Open
FY2024 Q1quarterly securities report2023-06-302023-08-07195Open
FY2023annual securities report2023-03-312023-06-27257Open
FY2023 Q3quarterly securities report2022-12-312023-02-09147Open
FY2023 H1quarterly securities report2022-09-302022-11-10192Open

Financial data

262 concepts · 3,379 facts

Each concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.

GAAP250 concepts · 2,976 facts · Mar 2021 to Sep 2026

  • EPS (Basic)37 · Jun 2021 to Sep 2026
  • Net Assets32 · Mar 2021 to Sep 2026
  • Cash and deposits31 · Jun 2021 to Sep 2026
  • Equity-to-asset ratio, Key financial data31 · Jun 2021 to Sep 2026
  • Investments and other assets31 · Jun 2021 to Sep 2026
  • Net assets, Key financial data31 · Jun 2021 to Sep 2026
  • Ordinary profit (loss), Key financial data31 · Jun 2021 to Sep 2026
  • Other-CA31 · Jun 2021 to Sep 2026
  • Other-CL31 · Jun 2021 to Sep 2026
  • Retained Earnings (Accumulated Deficit)31 · Jun 2021 to Sep 2026
  • Revenue31 · Jun 2021 to Sep 2026
  • Share capital31 · Jun 2021 to Sep 2026
  • Shareholders' equity31 · Jun 2021 to Sep 2026
  • Short-term borrowings31 · Jun 2021 to Sep 2026
  • Total Assets31 · Jun 2021 to Sep 2026
  • Total assets, Key financial data31 · Jun 2021 to Sep 2026
  • Total Current Assets31 · Jun 2021 to Sep 2026
  • Total Current Liabilities31 · Jun 2021 to Sep 2026
  • Total Equity and Liabilities31 · Jun 2021 to Sep 2026
  • Total Liabilities31 · Jun 2021 to Sep 2026
  • Total Noncurrent Assets31 · Jun 2021 to Sep 2026
  • Treasury shares31 · Jun 2021 to Sep 2026
  • Intangible assets29 · Jun 2021 to Sep 2026
  • Investment securities29 · Jun 2021 to Sep 2026

Segment12 concepts · 403 facts · Jun 2021 to Sep 2026

  • Operating Income88 · Jun 2021 to Sep 2026
  • Revenue88 · Jun 2021 to Sep 2026
  • Revenues from external customers71 · Jun 2021 to Sep 2026
  • Transactions with other segments51 · Jun 2021 to Sep 2026
  • Number of employees27 · Mar 2022 to Mar 2026
  • Total Assets27 · Mar 2022 to Mar 2026
  • Depreciation, Segment Information22 · Mar 2022 to Mar 2026
  • Average number of temporary employees17 · Mar 2022 to Mar 2026
  • Goodwill4 · Mar 2025 to Mar 2026
  • Impairment losses3 · Mar 2025
  • Impairment losses - EL3 · Mar 2022
  • Amortization of goodwill-SGA2 · Mar 2026

Segments

403 facts

Figures broken down by business line, region, product or another axis the company reports on.

Operating segments7 members · 403 facts

  • OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember83 · Jun 2021 to Sep 2026
  • TotalOfReportableSegmentsAndOthersMember83 · Jun 2021 to Sep 2026
  • PharmaceuticalBusinessReportableSegmentsMember73 · Jun 2021 to Sep 2026
  • AnimalHealthBusinessReportableSegmentsMember69 · Jun 2021 to Sep 2026
  • ReconcilingItemsMember61 · Jun 2021 to Sep 2026
  • OverseaBusinessReportableSegmentsMember19 · Mar 2025 to Sep 2026
  • CorporateSharedMember15 · Mar 2022 to Mar 2026

Text from filings

Management commentary and risk factors, extracted from SEC filings only.

No commentary or risk-factor text for this company.

Earnings calls

Transcripts with management claims and analyst questions, one per fiscal period.

No earnings-call transcripts for this company.

Executive media

Podcasts, interviews and conference appearances by the company's executives, with their claims.

No media appearances for this company.

Ask about this company in your AI model

Connect FactIQ to Claude, ChatGPT or another AI model (how to install), then paste this prompt.

Use FactIQ to get the revenue, net income and operating income of ASKA Pharmaceutical Holdings CO., Ltd. (4886.T) from its filed reports, for the last five fiscal years and the latest quarter or half year. Link each figure to its filing, and chart the trend.

Works once FactIQ is connected

Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Nov 19, 2026) and refreshed every few hours.

ASKA Pharmaceutical Holdings CO., Ltd. (4886.T): FY2026 revenue ¥71.1B · FactIQ